Emcure Pharma

Emcure Pharmaceuticals delivered a robust performance in Q1 FY26, with revenue growing by 15.7% year-on-year to INR 2,101 crores. EBITDA saw a 20.1% increase, reaching INR 404 crores, while PAT surged by 41% year-on-year to a record INR 215 crores. The company's gross margins stood at 61.8%, and EBITDA margins improved to 19.2% from 18.5% in Q1 FY24, reflecting strong operating leverage and productivity gains.

The domestic business grew faster than the industry, achieving a 9.4% year-on-year growth to INR 995 crores. This growth was broad-based, with strong performance across key therapies including Gynaec, Cardiac, Anti-infective, and Vitamins. New initiatives in Derma and consumer wellness are showing positive trends and are expected to become key growth drivers, contributing an additional 1-2% to overall domestic business growth for the year.

International business recorded a strong 22% year-on-year growth, reaching INR 1,106 crores. Emerging Markets led this growth with a 42% increase to INR 360 crores, driven by new product approvals in target countries. Canada grew by 16.4% to INR 342 crores, and Europe saw a 12.8% growth to INR 403 crores. The company is strengthening its non-ARV segment with unique products and expects a significant ramp-up of Liposomal Amphotericin B in Europe in H2 FY26.

Emcure expanded its partnership with Sanofi for the diabetes segment, marketing and distributing oral diabetic portfolio brands like Amaryl and Cetapin from August 1st. This move is strategic for strengthening Emcure's presence in the metabolic diabeto segment and leveraging existing doctor relationships for future launches like Semaglutide. The company is also progressing with Asparaginase and wet AMD products, with at least one approval expected this financial year, and Semaglutide filing in Canada by year-end.

Management aims to expand its EBITDA margin profile by 300-400 basis points over the next 4-5 years, targeting 23-24% by the end of this period. This improvement will be driven by productivity gains in the Indian field force, scaling of the business, better utilization of manufacturing facilities, and a favorable product mix. The company expects to achieve approximately 100 basis points of operating cost improvement this year.

The company's gross debt stands at INR 700 crores. While an initial target was to bring debt close to zero by the end of the current fiscal year, recent acquisitions of a product portfolio for Manx and a minority stake in Zuventus will push out this timeline by at least 1 to 1.5 years. Annualized capex spending is projected at INR 350 crores, with INR 150 crores for maintenance and INR 200 crores for capacity enhancements and product-specific requirements. Cash and cash equivalents as of June 30, 2025, were INR 200 crores.

Emcure highlighted its insulation from potential US market risks, noting that its exposure to the US is less than 3%. This position provides a buffer against any adverse impacts from potential US tariffs on Indian exports, which management acknowledged as a concern in the broader industry context.